MOS

$533 Million Semiconductor Wafer Polishing and Grinding Equipment Markets - Global Industry Trends, Share, Size, Growth, Opportunity and Forecasts 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
Technology, Semiconductor, R, COVID-19, IOT, Internet of things, MOS, Ion, Artificial intelligence, Electronics, Research, CMP, SOC, MEMS, Employment, Consumer electronics, Potash, Growth

The "Semiconductor Wafer Polishing and Grinding Equipment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Semiconductor Wafer Polishing and Grinding Equipment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global semiconductor wafer polishing and grinding equipment market reached a value of US$ 385.44 Million in 2021.
  • What has been the impact of COVID-19 on the global semiconductor wafer polishing and grinding equipment market?
  • What is the structure of the global semiconductor wafer polishing and grinding equipment market and who are the key players?

Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary

Retrieved on: 
Thursday, December 15, 2022
ESMO, Progression-free survival, Ovarian cancer, ISD, Maintenance, Death, ITT, OS, European Society for Medical Oncology, MOS, PARP, Data analysis, Oncology, HIV disease progression rates, Mutation, Risk, CI, Patient, PFS, Health insurance, Pharmaceutical industry

SHANGHAI, China and CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today presented new interim overall survival (OS) data in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC) from the Phase 3 NORA study for ZEJULA® (niraparib) at the European Society for Medical Oncology (ESMO) Virtual Plenary.

Key Points: 
  • mOS in the ITT population: 46.3 months for patients receiving ZEJULA versus 43.4 months for placebo group [HR=0.82; 95% CI, 0.56-1.21].
  • mOS in non-gBRCA mutation subgroup: 43.1 months for patients receiving ZEJULA versus 38.4 months for placebo group [HR=0.86; 95% CI, 0.53-1.38].
  • mOS in gBRCA mutation subgroup: Not reached for patients receiving ZEJULA versus 42.1 months [HR=0.88; 95% CI 0.39-2.01].
  • The NORA study was evaluated in 265 platinum-sensitive recurrent ovarian cancer patients randomized 2:1 to receive niraparib or placebo until disease progression.

MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology

Retrieved on: 
Thursday, December 15, 2022
Journal of Clinical Oncology, Beth Israel Deaconess Medical Center, Science in newly industrialized countries, Phase, Recurrence, Dana–Farber Cancer Institute, Oncology, Overlook Medical Center, MD, Baptist Health, Immunotherapy, American Journal of Clinical Oncology, Fred Hutchinson Cancer Research Center, Doctor of Philosophy, Diagnosis, Cleveland Clinic, UCSF Medical Center, Progression-free survival, Patient, JCO, Roswell Park Comprehensive Cancer Center, Survivin, NYU Langone Health, Hospital, Survival rate, Baptist Health South Florida, Disease, Phases of clinical research, MOS, Cancer, Texas Oncology, Massachusetts General Hospital, Survival, Manuscript, Journal, Multimedia, IIA, GBM, MBA, Pharmaceutical industry, Medical imaging, Medical device, Glioblastoma

SurVaxM was developed to bring a paradigm shift to a field with few advancements in recent years.

Key Points: 
  • SurVaxM was developed to bring a paradigm shift to a field with few advancements in recent years.
  • MimiVax announces positive Phase 2A SurVaxM data in GBM, 2yr survival rate of 51%, published in JCO
    This multi-center, open label, single arm, phase IIa trial in adult patients with nGBM was approved by the institutional review boards at each of the participating hospitals [NCT02455557].
  • Of 63 patients enrolled, 60 (95.2%) remained progression-free 6 months after diagnosis to successfully reach the study primary endpoint.
  • "These promising results seen in the Phase IIa study compare favorably to the historical contemporary outcomes seen in glioblastoma.

Taiho Oncology and Astex Pharmaceuticals Present Overall Survival Data for Oral Decitabine and Cedazuridine (INQOVI®, ASTX727) in Patients With MDS and CMML Harboring TP53 Mutations at 64th ASH Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Pneumonia, Intracranial hemorrhage, Society, Research, Toxicity, Anemia, Aplastic anemia, Child, Acute kidney injury, Ōtsuka, NCCN, Woman, Patient, Sepsis, MDS, Bone marrow suppression, Risk, CMML, Thrombocytopenia, Fatal, Microdeletion syndrome, MLF, International Prognostic Index, AUC, MOS, Birth, Febrile neutropenia, Clinical trial, National Comprehensive Cancer Network, Abstract, Neutropenia, Creatinine, ESRD, Pregnancy, De novo, Decitabine, Chronic kidney disease, TP53, Confidence interval, ASH, Mutation, Chronic myelomonocytic leukemia, Route of administration, Internal medicine, Sudden death, LFS, Kidney, Septic shock, Myelodysplastic syndrome, Vanderbilt University, Astex, Chromosomal deletion syndrome, IV, Fetus, Pharmaceutical industry, Birth control, Epidemiology, MD

PRINCETON, N.J. and PLEASANTON, Calif., Dec. 12, 2022 /PRNewswire/ -- Taiho Oncology, Inc. and Astex Pharmaceuticals, Inc. today announced preliminary data from the Phase 3 ASCERTAIN trial assessing overall and leukemia-free survival in adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML) harboring biallelic TP53 mutations following treatment with oral decitabine and cedazuridine (ASTX727). The data are being presented today as an oral presentation (Abstract #854) at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.

Key Points: 
  • The data are being presented today as an oral presentation ( Abstract #854 ) at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans.
  • In the study, the population of patients harboring a TP53 mutation (44 of 125 patients) was characterized by allelic status: 14 patients had biallelic mutations and 30 patients had monoallelic mutations without other chromosomal deletions.
  • The primary endpoint of the study was total 5-day area-under-the-curve (AUC) equivalence of oral decitabine and cedazuridine and IV decitabine.
  • Astex, the Astex logo, Taiho Oncology, the Taiho Oncology logo and INQOVI are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries.

Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Retrieved on: 
Monday, November 14, 2022
Patient, CRC, GMP, Skin, Angiosarcoma, University of Colorado School of Medicine, Toxic epidermal necrolysis, Infection, MSS, Platinum, Therapy, MOS, Sarcoma, SITC, GI, Research, Safety, Immune system, Security (finance), Data, Society, Society for Immunotherapy of Cancer, Risk, Annual report, Pancreatic cancer, University, NSCLC, Mink, Immunotherapy, Medical imaging, Pharmaceutical industry, Vaccine, Cancer, Agenus, Medicine

The data presented represents four of the most mature data sets from the nine cancer types where responses have been observed to date.

Key Points: 
  • The data presented represents four of the most mature data sets from the nine cancer types where responses have been observed to date.
  • The data was presented at a plenary session at the Society for Immunotherapy of Cancer (SITC) annual meeting and a company-hosted R&D event.
  • These data provide compelling support for our ongoing Phase 2 botensilimab development program and highlight the broad therapeutic potential of botensilimab across solid tumors.
  • Fixed dosing was also permitted whereby patients received botensilimab 150 mg every 6 weeks, and balstilimab 450 mg every 3 weeks.

VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

Retrieved on: 
Tuesday, November 22, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, FDA, Radiation, VLP, Education, Vaccine, Survival, Neoplasm, Fast track (FDA), Hepatitis B, GBM, Antigen, Infection, Cytomegalovirus, Patient, MOS, Virus, Human, Glioblastoma, VBI, Research, CMV, Data, Immune system, Society, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ASCO, Mortality, Learning, SNO, GB, Food, Pharmaceutical industry

We look forward to initiating randomized, controlled evaluation of VBI-1901 in the recurrent setting in early 2023.

Key Points: 
  • We look forward to initiating randomized, controlled evaluation of VBI-1901 in the recurrent setting in early 2023.
  • The data have subsequently been updated at the World Vaccine & Immunotherapy Congress in December 2021 and at ASCO 2022 .
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO

Retrieved on: 
Friday, November 18, 2022
Adult, Cancer, STS, MOS, Survival, Neoplasm, Safety, Immunohistochemistry, Death, BMS, Medicine, Poster, Columbia University, TTB, Therapy, Hematology, Patient, Division, Physician, Intensity, Columbia University Vagelos College of Physicians and Surgeons, Subbiah, Publication, College of Physicians and Surgeons, Sarcoma, Pharmaceutical industry, Ipilimumab, Surgeon

WESTPORT, Conn., Nov. 18, 2022 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its open-label phase 1/2 study of novel lead asset, INT230-6, as a monotherapy or in combination with ipilimumab in adult subjects with metastatic sarcomas, will be presented today in an oral podium presentation, at the Connective Tissue Oncology Society Annual Meeting (CTOS) being held at the Vancouver Convention Center in Vancouver, BC, Canada from November 16 -19, 2022.

Key Points: 
  • "To date, INT230-6 treatment related adverse events are mostly low grade and the drug is well-tolerated either as a monotherapy or in combination with ipilimumab.
  • The promising data supports our belief that INT230-6 could show clinical benefit with lower levels of off-target side effects compared to standard chemotherapies.
  • The data presented included results from 29 patients with different metastatic sarcomas treated with INT230-6 either as a monotherapy (n=15), or in combination with ipilimumab (n=14).
  • Subjects receiving combination with ipilimumab have not yet reached median survival with 345 days median follow-up.

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

Retrieved on: 
Thursday, November 17, 2022
Vaccination, JAMA Oncology, MOS, OTCQB, Recurrence, Survival, Neoplasm, Autologous tumor cell, Patient, Biotechnology, Northwest Biotherapeutics, Physician, Glioblastoma, Hope, Standard of care, Extension, HR, Phase, GBM, SOC, Diagnosis, Medical imaging, Pharmaceutical industry

BETHESDA, Md., Nov. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported that in its Phase III clinical trial both median survival and the "long tail" of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L. The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial.

Key Points: 
  • The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial.
  • The Company's lead program is a 331-patient Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM).
  • It has completed a 40-patient Phase I trial and plans to prepare for Phase II trials as resources permit.
  • The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

Retrieved on: 
Thursday, November 17, 2022
Vaccination, JAMA Oncology, MOS, OTCQB, Recurrence, Survival, Neoplasm, Autologous tumor cell, Patient, Biotechnology, Northwest Biotherapeutics, Physician, Glioblastoma, Hope, Standard of care, Extension, HR, Phase, GBM, SOC, Diagnosis, Medical imaging, Pharmaceutical industry

BETHESDA, Md., Nov. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported that in its Phase III clinical trial both median survival and the "long tail" of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L. The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial.

Key Points: 
  • The trial has met both the primary and the secondary endpoint under the Statistical Analysis Plan for the trial.
  • The Company's lead program is a 331-patient Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM).
  • It has completed a 40-patient Phase I trial and plans to prepare for Phase II trials as resources permit.
  • The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

Semiconductor Materials Market To Reach USD 52410 Million By 2028 at a CAGR of 3.3%| Valuates Reports

Retrieved on: 
Monday, November 14, 2022
Internet, Growth, IOT, Government, Defense, Global, Data storage, United States Department of Defense aerospace vehicle designation, Semiconductor, Silicon, CAGR, Efficiency, Industry, Aircraft, Wireless, VLF, Research, Communication, MOS, Gallium arsenide, Computer, Electronics, Automotive industry, USD, Wireless Industrial Networking Alliance, Final good, APAC, Memory, Telecommunication, Mobile phone, Computer data storage, Consumer electronics

The global Semiconductor Materials Market is projected to reach USD 52410 million by 2028, from USD 40420 million in 2021, at a CAGR of 3.3% during 2022-2028.

Key Points: 
  • The global Semiconductor Materials Market is projected to reach USD 52410 million by 2028, from USD 40420 million in 2021, at a CAGR of 3.3% during 2022-2028.
  • The Semiconductor Materials Market is anticipated to grow as demand from the Automotive, Data Storage, and Wireless Industries increases.
  • The demand for a more sophisticated product continues to drive market vendors and end-user organizations to spend on the creation of semiconductor materials, notwithstanding the semiconductor industry's fluctuating revenue growth.
  • Increasing demand for semiconductors from the Automotive industry is expected to drive the growth of the Semiconductor Materials Market.